Robert F. Kushner
Internal Medicine
259 E Erie St 16th Fl
Lavin Family Pavilion
Chicago, IL 60611
Lavin Family Pavilion
Chicago, IL 60611
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Comprehensive Obesity Management Part 2: Ongoing Assessment and Individualization of the Treatment Plan.
Journal: Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Published: August 28, 2026
Comprehensive Obesity Management Part 1: Assessment and Initiation of Treatment.
Journal: Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Published: August 28, 2026
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Journal: Nature medicine
Published: June 24, 2026
Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.
Journal: Diabetes, obesity & metabolism
Published: May 16, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Journal: Nature medicine
Published: April 22, 2026
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
Journal: Diabetes, obesity & metabolism
Published: April 17, 2026
Fixed-dose, extended-release combination of naltrexone and bupropion reduces craving and body weight: A pooled post hoc analysis.
Journal: Obesity research & clinical practice
Published: March 30, 2026
Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis.
Journal: Obesity science & practice
Published: March 20, 2026
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
Journal: The lancet. Diabetes & endocrinology
Published: March 12, 2026
Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.
Journal: Diabetes, obesity & metabolism
Published: February 24, 2026
Therapies based on GLP-1 receptor agonists: significance, challenges, and opportunities.
Journal: The Lancet. Global health
Published: December 15, 2025
Last Updated: 09/26/2026